» Articles » PMID: 17139495

Oral Mucositis and Outcomes of Allogeneic Hematopoietic Stem-cell Transplantation in Patients with Hematologic Malignancies

Overview
Specialties Critical Care
Oncology
Date 2006 Dec 2
PMID 17139495
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

Goals Of The Work: To assess the relationship between oral mucositis (OM) and adverse clinical and economic outcomes in patients with hematologic malignancies receiving allogeneic hematopoietic stem-cell transplantation (HSCT).

Materials And Methods: A retrospective chart review study of 281 allogeneic HSCT recipients with hematologic malignancies was undertaken at a single academic center. OM extent and severity were assessed across eight oropharyngeal sites using a validated scale, which was scored as follows: no erythema/ulceration=0; erythema only=I; ulceration, one site=II; ulceration, two sites=III; ulceration, three sites=IV and ulceration, four or more sites=V. OM assessments began on the day of conditioning and continued twice weekly within 28 days or hospital discharge. Analyses examined the relationship between the worst OM grade and selected adverse outcomes, including days with fever, days of total parenteral nutrition (TPN), days of parenteral narcotic therapy, incidence of significant (common terminology criteria (CTC) grade 3 or 4) infection, mortality and inpatient days and charges.

Main Results: The mean age of the study subjects was 41 years. Of the patients, 96% (n = 269) received total body irradiation and 76% (n = 214) experienced an OM grade of > or =II (i.e., ulceration). The worst OM grade was significantly (p < 0.05) associated with the number of days of TPN and parenteral narcotic therapy, number of days with fever, incidence of significant infection, time in hospital and total inpatient charges.

Conclusions: OM is associated with worse clinical and economic outcomes in patients with hematologic malignancies undergoing allogeneic HSCT.

Citing Articles

Efficacy of palifermin in the treatment of oral mucositis in non-hematopoietic stem cell transplant pediatric patients: experience of a single tertiary hospital.

Hamzi H, Binhassan A, Najmeldin A, Alhariri E, Elhussein B, Althibani N J Egypt Natl Canc Inst. 2024; 36(1):38.

PMID: 39617846 DOI: 10.1186/s43046-024-00247-x.


Oral foci of infection and their relationship with hospital stay after haematopoietic cell transplantation.

van Gennip L, Thomas R, Bulthuis M, Hannink G, Bronkhorst E, Blijlevens N Support Care Cancer. 2024; 32(12):816.

PMID: 39578296 PMC: 11584470. DOI: 10.1007/s00520-024-08991-5.


Efficacy of Episil® in patients with hematologic malignancies: a comparative study.

Fukutani T, Yoshioka Y, Imori S, Yanagihara H, Sumi K, Myoken Y BMC Oral Health. 2024; 24(1):522.

PMID: 38698387 PMC: 11067080. DOI: 10.1186/s12903-024-04233-6.


Preventive versus curative photobiomodulation for oral mucositis in patients with multiple myeloma undergoing hematopoietic stem cell transplantation: which approach is more effective?.

Rupel K, Cornacchia A, Poiani M, Mohamed S, De Bellis E, Ballerini M Support Care Cancer. 2024; 32(3):208.

PMID: 38438625 DOI: 10.1007/s00520-024-08414-5.


A randomized phase II study of acyclovir for the prevention of chemotherapy-induced oral mucositis in patients undergoing autologous hematopoietic stem cell transplantation.

Hong J, Park H, Chang S, Byun J, Shin D, Koh Y BMC Oral Health. 2023; 23(1):1008.

PMID: 38102638 PMC: 10724996. DOI: 10.1186/s12903-023-03623-6.


References
1.
Elting L, Cooksley C, Chambers M, Cantor S, Manzullo E, Rubenstein E . The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer. 2003; 98(7):1531-9. DOI: 10.1002/cncr.11671. View

2.
Bellm L, Epstein J, MARTIN P, Fuchs H . Patient reports of complications of bone marrow transplantation. Support Care Cancer. 2000; 8(1):33-9. DOI: 10.1007/s005209900095. View

3.
Sonis S, Oster G, Fuchs H, Bellm L, BRADFORD W, Edelsberg J . Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001; 19(8):2201-5. DOI: 10.1200/JCO.2001.19.8.2201. View

4.
Rapoport A, Miller Watelet L, Linder T, Eberly S, Raubertas R, Lipp J . Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol. 1999; 17(8):2446-53. DOI: 10.1200/JCO.1999.17.8.2446. View

5.
Hwang W, Koh L, Ng H, Tan P, Chuah C, Fook S . A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2004; 34(1):51-6. DOI: 10.1038/sj.bmt.1704521. View